US03835L3069 - Common Stock
APTEVO THERAPEUTICS INC
NASDAQ:APVO (4/25/2024, 6:37:21 PM)
Premarket: 0.68 0 (0%)0.68
0 (-0.38%)
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 45 full-time employees. The company went IPO on 2016-07-20. The company is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. The company has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.
APTEVO THERAPEUTICS INC
2401 4th Ave Ste 1050
Seattle WASHINGTON 98121
P: 12068380500
CEO: Marvin L. White
Employees: 45
Website: http://aptevotherapeutics.com/
Top movers analysis one hour before the close of the markets on 2024-04-11: top gainers and losers in today's session.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Thursday's session: gap up and gap down stocks
Hub Cyber Security stock is falling on Thursday after the company noted an investor sold a large stake of its HUBC shares.
Thursday's pre-market session: top gainers and losers
Aptevo Therapeutics stock is falling on Thursday after the company priced a public offering for 3.4 million shares of APVO.
Here you can normally see the latest stock twits on APVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: